Skip to primary content
Skip to secondary content

Biotech 365

Main menu

  • Biotech 365
  • Companies
  • Healthcare Investors
    • Healthcare LPs
  • Healthcare Investors Matchmaking
  • Free DEMO
  • Services
    • Preclinical Studies Database
    • Scientific Due Diligence
    • CRO & CDMO Database
  • Contact

Tag Archives: ALCLS

Cellectis – gene-editing

Posted on by

Cellectis is a biotech company focused on developing immunotherapies based on gene edited engineered CAR-T cells (UCART).

Cellectis – gene-editing

Cellectis

Continue reading →

Posted in Biotech Companies, Biotech Companies France | Tagged Acute lymphoblastic leukemia, Acute myeloid leukemia, adoptive immunotherapies, adoptive immunotherapy, Alain Godard, ALCLS, ALL, allogeneic T cells engineered, AML, André Choulika, Annick Schwebig, autologous adoptive immunotherapies, autologous adoptive immunotherapy, B cells malignancies, CAR, CAR-engineered cell, Cellectis, Cellectis - gene-editing, Chimeric Antigen Receptor, Chronic lymphocytic leukemia, CLL, David Sourdive, electroporation PulseAgile technology, engineered nuclease, engineered nucleases, gene edited engineered CAR-T cell, gene edited engineered CAR-T cells, gene edited engineered T cell, gene engineering, gene-editing, genome engineering, glioblastoma, immunotherapies, immunotherapy, Laurent Arthaud, leukemia, Mathieu Simon, meganuclease, meganucleases, Multiple myeloma, non-small-cell lung cancer, pancreatic cancer, Philippe Duchateau, Pierre Bastid, PulseAgile, T cells, T-cell, TALEN, TALEN products, Thierry Moulin, UCART

        Services              Healthcare Investors Database              FAQs               CGU               Biotech & Pharma News             Contact
Proudly powered by WordPress